New RA drug KD6005 enters first human tests
NCT ID NCT06213259
First seen Apr 03, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This early-stage study tested a new drug called KD6005 in 73 people. First, healthy volunteers received a single dose to check safety. Then, people with rheumatoid arthritis received multiple doses. The main goal was to see if the drug is safe and how the body processes it. This is a first step; more research is needed to know if it helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University People's Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.